Prelude Therapeutics Inc PRLD

US Biotechnology

$4.60 ▼ -8.91% ($-0.45)

⬇️ Below Yest. Low 🗓️ Earnings Next Week

Open $5.03

Prev Close $5.05

Day Range $4.57 – $5.15

52W Range $0.75 – $5.69

Market Cap $366.37M

Beta 0.93

EPS (TTM) $-0.59

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2020-09-25
Shares Out.	79,650,000
Website	preludetx.com/ ↗
Phone	13026589200
Employees	79
Revenue	$4.6M
Gross Profit	$4.6M
Net Income	-$10.4M
Free Cash Flow	-$43.8M
Total Assets	$119.6M
Total Liabilities	$59.5M
Equity	$60.2M

About Prelude Therapeutics Inc

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

Prelude Therapeutics Inc is a publicly traded company under the ticker symbol PRLD on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.